Prof. Dr. Jong-Sup Bae | Pharmaceutical Sciences | Best Paper Award

Professor at Kyungpook National University, South Korea.

Dr. Jong-Sup Bae is a distinguished professor of pharmaceutical sciences at Kyungpook National University, Republic of Korea, with a global reputation in drug development, molecular pharmacology, and translational research. He has published over 350 SCI-indexed papers, including high-impact journals such as Blood, PNAS, Advanced Materials, and Science Advances, with over 12,749 citations and an h-index of 57. His leadership roles include Director of the Research Institute of Pharmaceutical Sciences and Dean of the College of Pharmacy. His extensive work in developing therapeutic agents and biomaterials is backed by 71 patents (15 international and 56 domestic). He has been honored with prestigious awards, including the Minister of Health and Welfare Award and multiple Most Cited Paper Awards. His pioneering contributions continue to shape the landscape of pharmaceutical sciences in Korea and globally.

Professional Profile

Scopus

Suitability For Best Paper Award – Prof. Dr. Jong-Sup Bae

Dr. Jong-Sup Bae, a renowned professor at Kyungpook National University, is exceptionally well-qualified for the Best Paper Award. His candidacy is supported by a stellar academic track record comprising over 350 SCI-indexed publications, 12,749 citations, and a high h-index of 57—clear indicators of sustained scholarly impact. His key contributions include cutting-edge research in molecular pharmacology, nanomedicine, and inflammatory disease mechanisms, all published in top-tier journals like Science Advances, Advanced Materials, Blood, and PNAS. A standout contribution is his recent work on 3-Deoxysappanchalcone, which demonstrates novel anti-thrombotic mechanisms with potential therapeutic application—precisely the kind of innovation this award seeks to honor.

Dr. Jong-Sup Bae’s strength lies in his ability to translate molecular discoveries into therapeutic candidates, leveraging advanced drug delivery systems and bioinformatics. His work consistently bridges basic science and translational outcomes. Notably, he holds 71 patents, highlighting the originality and applied value of his research.

Additionally, his role as Director of the Research Institute of Pharmaceutical Sciences and Dean of the College of Pharmacy amplifies his influence on research strategy and mentoring. Multiple recognitions—including the Minister of Health and Welfare Award, Science and Technology Excellent Paper Award, and Most Cited Paper Awards—attest to his national and international research excellence.

Education

Dr. Jong-Sup Bae received rigorous training in pharmaceutical sciences and biomedical research through an integrated academic path that laid the foundation for his translational and interdisciplinary research. He earned his bachelor’s and master’s degrees in pharmaceutical sciences, followed by a Ph.D. in pharmacology or a related field (exact details not provided in your data; please confirm). During his academic journey, he specialized in molecular pharmacology, drug development, and bioactive compounds, receiving advanced training in both laboratory and clinical-oriented research methodologies. His doctoral work was instrumental in developing a strong foundation in pharmacokinetics, cellular signaling pathways, and therapeutic design. This educational background has enabled him to pursue impactful research at the interface of molecular medicine and pharmacotherapy, influencing future drug candidates and treatment modalities. His academic excellence has been reflected in both teaching and research capacities, forming a strong base for his career in academia and pharmaceutical innovation.

Experience

Dr. Jong-Sup Bae has accumulated over 17 years of academic and research experience in pharmaceutical sciences. He served as Assistant Professor in the Department of Pharmaceutical Engineering at Daegu Haany University. He has held progressive academic positions—Assistant Professor, Associate Professor, and currently Full Professor—at the College of Pharmacy, Kyungpook National University. His appointment as Director of the Research Institute of Pharmaceutical Sciences and as Dean of the College reflects his strategic leadership in advancing Korea’s pharmaceutical research ecosystem. His laboratory focuses on molecular mechanisms of disease and the development of innovative drug delivery systems. Under his mentorship, numerous graduate students and postdoctoral researchers have made notable scientific contributions. He also plays an editorial role in leading journals and contributes to national research initiatives and government-led scientific projects, positioning himself as a prominent figure in pharmaceutical and biomedical research.

Professional Development

Dr. Jong-Sup Bae has consistently advanced his professional standing through research leadership, scholarly output, and academic administration. His career trajectory reflects excellence in teaching, mentorship, publication, and innovation. As Dean and Director, he has championed interdisciplinary collaboration and promoted translational research. His international patents and high-impact publications demonstrate an ability to move from fundamental discovery to clinical application. He actively participates in scientific conferences, editorial boards, and academic societies, strengthening both his knowledge and professional network. Notably, his roles as Editor for Biotechnology and Bioprocess Engineering and advisor to scientific bodies position him at the forefront of pharmaceutical innovation. His proactive involvement in governmental and institutional research programs underscores his commitment to public health and policy-oriented science. Through these initiatives, he not only fosters institutional growth but also contributes to the global scientific community by mentoring emerging scholars and advancing pharmaceutical sciences in South Korea and beyond.

Research Focus

Dr. Jong-Sup Bae specializes in translational pharmaceutical research with a particular focus on molecular pharmacology, drug discovery, nanomedicine, and inflammatory disease mechanisms. His research aims to elucidate cellular signaling pathways related to inflammation, thrombosis, and metabolic disorders to develop effective therapeutic candidates. He has pioneered work on drug delivery systems, including nanoparticle-based formulations and targeted delivery for anti-inflammatory and anti-thrombotic agents. His investigations often bridge basic molecular insights with clinical relevance, evidenced by the development of compounds like 3-Deoxysappanchalcone for anti-thrombotic activity. His team’s work has led to innovative therapies published in top-tier journals such as Science Advances, Biomaterials, and Advanced Functional Materials. Dr. Jong-Sup Bae’s research focus also includes immune modulation, respiratory diseases, and renal pharmacology, reflecting a broad yet integrated scientific agenda. Through strategic collaborations, he continues to advance the development of next-generation pharmaceuticals with both academic and industrial impact.

Research Skills

Dr. Jong-Sup Bae possesses an extensive range of research skills centered around molecular biology, pharmacokinetics, bioinformatics, drug screening, and nanotechnology-based drug delivery systems. He is adept in cell culture techniques, gene/protein expression analysis (e.g., Western blotting, qPCR), and molecular docking. His group employs in vivo and in vitro models to study disease mechanisms and drug efficacy, especially in inflammation, thrombosis, and metabolic diseases. He has strong expertise in formulating novel drug delivery carriers such as nanoparticles and hydrogels to enhance bioavailability and targeting precision. Furthermore, he integrates systems biology and omics approaches to identify therapeutic targets. With a solid grasp of patent writing and regulatory aspects, he has translated his research into over 70 patents. His skills also extend to mentoring, grant writing, and international collaboration, making him a versatile and strategic researcher who consistently delivers high-impact scientific outcomes.

Awards and Honors

Dr. Jong-Sup Bae has been recognized with over 15 prestigious awards celebrating his scientific excellence and innovation. Among these are multiple “Most Cited Paper Awards” and “Academic Journal Achievement Awards” from BMB Reports, highlighting his consistent scholarly impact. He was honored with the “Young Pharmacist Award” by The Pharmaceutical Society of Korea and the “Minister of Health and Welfare Award,” reflecting both academic and societal contributions. His work has also earned the “Top 5 Domestic Bio Research Achievements” by BRIC and the “Science and Technology Excellent Paper Award” by the Korean Federation of Science and Technology Societies. As the recipient of the Blue Ribbon Lectureship and the Beomseok Thesis Award, his early career promise has matured into sustained excellence. His accolades reflect peer recognition at the national and international levels, solidifying his reputation as a leader in pharmaceutical sciences.

Publication Top Notes

Title: Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity
Journal: Molecules
Summary:
This study shows that 3-deoxysappanchalcone (3-DSC) significantly inhibits platelet aggregation and coagulation by targeting thrombin (FIIa) and factor Xa (FXa). The dual inhibition highlights its potential as a promising anti-thrombotic compound.

Title: 3-Deoxysappanchalcone Inhibited High Mobility Group Box Protein 1-Mediated Severe Inflammatory Responses
Journal: Pharmaceuticals
Citation Count: 1
Summary:
3-DSC suppressed HMGB1-induced inflammation by downregulating pro-inflammatory cytokines and blocking NF-κB activation. This suggests its potential role in managing HMGB1-related inflammatory disorders.

Title: Guillain-Barré Syndrome during the COVID-19 Era: A Nationwide Study of Hospitalized Cases in South Korea
Journal: Medicine (United States)
Summary:
A large-scale analysis of GBS cases in South Korea during the COVID-19 pandemic revealed changing incidence and clinical features, possibly associated with SARS-CoV-2 infection. The study offers epidemiological insights into virus-related neurological disorders.

Title: The Beneficial Effects of CGK012 Against Lipopolysaccharide-Induced Inflammation
Journal: Journal of Medicinal Food
Summary:
CGK012 was shown to suppress LPS-induced inflammation by inhibiting TNF-α and IL-6 production and blocking NF-κB signaling. These anti-inflammatory properties suggest therapeutic promise in inflammatory diseases.

Title: The Guanine Nucleotide Exchange Factor DOCK5 Negatively Regulates Osteoblast Differentiation and BMP2-Induced Bone Regeneration via the MKK3/6 and p38 Signaling Pathways
Journal: Experimental and Molecular Medicine
Citation Count: 2
Summary:
DOCK5 impairs osteoblast differentiation and bone regeneration by suppressing BMP2-mediated activation of the MKK3/6-p38 MAPK pathway. Inhibition of DOCK5 may enhance bone healing.

Title: Inhibitory Effects of Decursin Derivative Against Lipopolysaccharide-Induced Inflammation
Journal: Pharmaceuticals
Citation Count: 2
Summary:
The decursin derivative significantly reduced inflammatory markers in an LPS-induced model by targeting MAPK and NF-κB pathways, confirming its potential as an anti-inflammatory compound.

Title: Glycinamide Facilitates Nanocomplex Formation and Functions Synergistically with Bone Morphogenetic Protein 2 to Promote Osteoblast Differentiation In Vitro and Bone Regeneration in a Mouse Calvarial Defect Model
Journal: Tissue Engineering and Regenerative Medicine
Citation Count: 1
Summary:
Glycinamide synergizes with BMP2 to enhance osteoblast differentiation and bone healing in a skull defect model. It also aids in nanocomplex formation, improving therapeutic delivery.

Title: Suppressive Activities of Lupeol on Sepsis Mouse Model
Journal: Biotechnology and Bioprocess Engineering
Citation Count: 1
Summary:
Lupeol reduced mortality and systemic inflammation in a sepsis model by lowering pro-inflammatory cytokine levels. The compound shows promise as a protective agent in sepsis therapy.

Title: The Beneficial Effects of Lupeol on Particulate Matter–Mediated Pulmonary Inflammation
Journal: Food and Chemical Toxicology
Citation Count: 2
Summary:
Lupeol mitigated lung inflammation caused by airborne particulate matter. It reduced oxidative stress and inflammatory cytokines, indicating its potential in respiratory protection.

Title: Napyradiomycin B4 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Alveolar Bone Destruction in Experimental Periodontitis
Journal: ACS Pharmacology and Translational Science
Citation Count: 3
Summary:
Napyradiomycin B4 inhibits RANKL-induced osteoclast formation and prevents bone loss in periodontitis models. It offers therapeutic value in treating bone-destructive conditions.

Conclusion:

Dr. Jong-Sup Bae is not only a prolific and high-impact researcher but also a translational innovator whose contributions have advanced pharmaceutical sciences significantly. His recent high-caliber publications, especially in disease-modifying drug development, strongly qualify him for the Best Paper Award. His achievements embody the award’s goals: to recognize originality, scientific rigor, and real-world impact in pharmaceutical research. Therefore, he is an outstanding and deserving candidate for the Best Paper Award.